SCHEMBL16216730

SCHEMBL16216730

Cc1ccc(Oc2ccc(C3CCCCC3)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 1/20 0.51
ALDH1A1 P00352 4/20 0.50
MAPT P10636 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 2/20 0.50
TP53 P04637 1/20 0.50
ATM Q13315 1/20 0.50
MMP13 P45452 1/20 0.47
SLC18A3 Q16572 1/20 0.46
TEAD4 Q15561 1/20 0.45
KCNH2 Q12809 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
POLB P06746 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
KDM4E B2RXH2 1/20 0.42
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6704196 0.90 HAO1 (0.59) HAO1ALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL346325 0.88 LMNA (0.59) HAO1ALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL8025878 0.88 LMNA (0.59) HAO1ALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL28722738 0.88 LMNA (0.59) HAO1ALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL43080 0.85 SLC18A3 (0.56) ALDH1A1MAPTSMN1; SMN2LMNATP53
SCHEMBL11179383 0.85 ALDH1A1 (0.55) HAO1ALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL14231502 0.83 ESR2 (0.53) HAO1ALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL7702531 0.82 HAO1 (0.53) HAO1ALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL16015355 0.82 HAO1 (0.43) HAO1ALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL18117721 0.82 MAPT (0.54) ALDH1A1MAPTSMN1; SMN2LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030855-B2 Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts CELLESTIA BIOTECH AG (CH) 2024-07-09 US disclosed
US-9296682-B2 Inhibitors of notch signalling pathway and use thereof in treatment of cancers ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2016-03-29 US disclosed
US-20140329867-A1 INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) 2014-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329867-A1 INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS NOTCH3, NOTCH1, NOTCH4 HAO1 3641/4885ALDH1A1 2582/4885MAPT 3407/4885
US-12030855-B2 Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts ADH1C, ADH1A, DDC HAO1 3372/4885ALDH1A1 42/4885MAPT 2229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.